The Daily Biotech Pulse: Eloxx Resumes Cystic Fibrosis Study, Rexahn’s Reverse Merger, Ultragenyx, Epizyme Await FDA Decisions Benzinga
Form S-1/A Kaleyra, Inc. StreetInsider.com
Form S-1/A Kaleyra, Inc. – StreetInsider.com Read More »
40 Stocks Moving in Thursday’s Pre-Market Session Benzinga
40 Stocks Moving in Thursday's Pre-Market Session – Benzinga Read More »
BRIEF-Iveric Bio Inc Announces Pricing Of Upsized Public Offering Of Common Stock at $4.100 Per Share Reuters
Rexahn and Ocuphire Enter into Definitive Merger Agreement GlobeNewswire
Rexahn and Ocuphire Enter into Definitive Merger Agreement – GlobeNewswire Read More »
VerifyMe Announces Pricing of $10.0 Million Public Offering, Uplisting to NASDAQ and 50-to-1 Reverse Stock Split Benzinga
Brickell Biotech, Inc. Announces Pricing of $20.1 Million Underwritten Public Offering GlobeNewswire
TSX Venture Exchange Stock Maintenance Bulletins Yahoo Finance
TSX Venture Exchange Stock Maintenance Bulletins – Yahoo Finance Read More »
IT Tech Packaging : ITP Annual Report 2019.pdf Marketscreener.com
IT Tech Packaging : ITP Annual Report 2019.pdf – Marketscreener.com Read More »
Pulse Biosciences, Inc. Announces Closing of $30 Million Rights Offering BioSpace
Pulse Biosciences, Inc. Announces Closing of $30 Million Rights Offering – BioSpace Read More »